Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Brunner, TB; Rupp, A; Melzner, W; Grabenbauer, GG; Sauer, R.
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
Strahlenther Onkol. 2008; 184(1):15-22
Doi: 10.1007/s00066-008-1787-5
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: To present the results of a prospective phase II study in esophageal carcinoma. PATIENTS AND METHODS: Patients received single doses of 1.8 Gy up to 27 Gy, then concomitant boost to a total of 50.4 Gy (PTV2 [planning target volume], single dose 1.8 Gy) and 64.8 Gy (PTV1, single dose 1.2 Gy in the morning and 1.8 Gy in the afternoon) concurrently with 800 mg/m(2)/d 5-fluorouracil and 20 mg/m(2)/d cisplatin (weeks 1 and 5). High-dose-rate brachytherapy (2-3 x 6 Gy) on Fridays of weeks 4-6 used a customized applicator facilitating central placement and circumferential dose homogeneity. RESULTS: 50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1). Median overall survival (median OS 16 months; 1-year-OS 61%; 2-year OS 29%) was significantly longer for patients without nodal disease (35 vs. 11 months; p = 0.01). Hematotoxicity was grade 3 in 11/50, and grade 4 in 1/50 patients. Four percent of higher-grade nausea or vomiting occurred. Esophageal late toxicity was grade 3 in 9/50 patients, and grade 4 in 2/50 patients. CONCLUSION: Survival was excellent especially for patients without nodal disease in this dose-intensified schedule with acceptable tolerability.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - drug therapy, radiotherapy
- Adult - administration & dosage
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Brachytherapy - methods
- Carcinoma, Squamous Cell - drug therapy, mortality, pathology, radiotherapy
- Cisplatin - administration & dosage
- Combined Modality Therapy - administration & dosage
- Esophageal Neoplasms - drug therapy, mortality, pathology, radiotherapy
- Esophagus - radiation effects
- Female - administration & dosage
- Fluorouracil - administration & dosage
- Follow-Up Studies - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Neoplasm Staging - administration & dosage
- Prospective Studies - administration & dosage
- Radiation Injuries - etiology
- Radiotherapy Planning, Computer-Assisted - administration & dosage
- Radiotherapy, Conformal - administration & dosage
- Radiotherapy, High-Energy - administration & dosage
- Survival Rate - administration & dosage
- Find related publications in this database (Keywords)
- chemoradiotherapy
- concomitant boost
- high-dose-rate endoluminal brachytherapy
- esophageal cancer
- phase II study